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Abstract There is a considerable and growing unmet medical need in respiratory
disease concerning effective anti-inflammatory therapies for conditions such
as severe asthma, chronic obstructive pulmonary disease and cystic fibrosis.
These diseases share a predominant characteristic of an enhanced and un-
controlled inflammatory response in the lungs, which contributes to disease
progression, hospitalization and mortality. These diseases are poorly con-
trolled by current anti-inflammatory therapies including glucocorticoids,
which are otherwise effective in many other inflammatory conditions or in
milder disease such as asthma. The exact cause of this apparent impairment of
glucocorticoid function remains largely unclear; however, recent studies have
now implicated a number of possible mechanisms. Central among these is an
elevation of the oxidant burden in the lungs and the resulting reduction in the
activity of histone deacetylase (HDAC)-2. This contributes to both the en-
hancement of proinflammatory mediator expression and the impaired ability
of the glucocorticoid receptor (GR)-a to repress proinflammatory gene ex-
pression. The oxidant-mediated reduction in HDAC-2 activity is, in part, a
result of an elevation in the phosphoinositol 3-kinase (PI3K) d/Akt signalling
pathway. Blockade of the PI3Kd pathway restores glucocortiocoid function
in both in vitro and in vivo models, and in primary cells from disease. In
addition, inhibition of the PI3Kd and PI3Kg isoforms is anti-inflammatory in
both innate and adaptive immune responses. Consequently, selective inhibi-
tion of this pathway may provide a therapeutic strategy both as a novel anti-
inflammatory and in combination therapy with glucocorticoids to restore
their function. However, a number of other oxidant-related and -unrelated
mechanisms, including altered kinase signalling and expression of the domin-
ant negative GRb, may also play a role in the development of glucocorticoid
insensitivity. Further elucidation of these mechanisms and pathways will
enable novel therapeutic targeting for alternative anti-inflammatory drugs
or combination therapies providing restoration for the anti-inflammatory
action of glucocorticoids.
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1. Overview of Glucocorticoid
Insensitivity in Airway Diseases:
Medical Need
Glucocorticoids are effective anti-inflammatory
drugs that are used to control both acute and
chronic inflammatory responses in a wide range
of diseases. However, in some diseases the anti-
inflammatory actions of glucocorticoids are im-
paired or ineffective. These include depression,
inflammatory bowel disease, multiple sclerosis,
rheumatoid arthritis, acute lymphoblastic leukae-
mia, cystic fibrosis (CF), idiopathic pulmonary
fibrosis, severe asthma and chronic obstructive
pulmonary disease (COPD).[1-7] Respiratory dis-
eases are predominant amongst these and their
incidence, particularly severe asthma and COPD,
are increasing.[8,9] The problem of relative gluco-
corticoid insensitivity in these diseases is
compounded by the fact that the precise im-
munological and molecular mechanisms of these
diseases remain complex and unclear.[10] Current
anti-inflammatory therapies for severe asthma,
COPD and CF are inadequate, which highlights a
substantial unmet medical need with significant
disease management problems and cost burden
for healthcare systems worldwide. Recent at-
tempts to find effective anti-inflammatory alter-
natives, such as anti-tumour necrosis factor
(TNF)-a agents for COPD, have proven un-
successful and place some doubt on the reliability
of ‘single target’ therapies in complex and poorly
understood inflammatory diseases.[11] In addi-
tion, the incidence of a relative glucocorticoid
insensitivity is seen in a wide range of diseases, yet
many of these harbour ‘similar’ characteristics
including oxidative stress and innate immunity.
Therefore, the likelihood of at least some degree
of mechanistic commonality is large; this remains
unaddressed but would be important in develop-
ing a therapeutic strategy with a broad disease
application.
In this review we aim to introduce the reader to
glucocorticoids, their mechanism of action and
the basic pathophysiologies of COPD, severe asth-
ma and CF. In addition, we aim to describe the
phenomenon of relative glucocorticoid insensiti-
vity in these diseases, including proposed mech-
anisms and thereafter potential anti-inflammatory
therapeutic strategies.
2. Glucocorticoids: Mechanism of Action
Glucocorticoids mediate a broad-ranging
immunosuppression through binding and acti-
vation of the glucocorticoid receptor (GR)-a.
Non-glucocorticoid bound GRa is sequestered in
the cytosol by a complex of chaperone proteins
including heat shock proteins 70 and 90, which pre-
vent non-ligand-mediatedGRa activity.[12,13] Asso-
ciation with this complex enables GRa to adopt
the correct conformation to allow glucocorticoid
binding.[13] Upon glucocorticoid binding, GRa
dissociates from this complex and translocates to
the nucleus where it mediates both repression and
induction of gene expression (figure 1).[14,15] The
exact contributions of GRa-mediated gene re-
pression (transrepression) and gene activation
(transactivation) to the anti-inflammatory ac-
tions of glucocorticoids remain unresolved and
controversial, but may be stimulus dependent.[16]
There is also increasing evidence for rapid ‘non-
genomic’ glucocorticoid actions thatmay arise from
(i) specific interactions with as yet unidentified
cell surface receptors or (ii) direct action in the cell
lipid membrane.[17,18] These non-genomic actions
are proposed to lead to rapid signalling through the
generation of secondary signalling messengers and
thereafter influencing signalling pathways.[17] How-
ever, investigation into these non-genomic mech-
anisms are in their infancy and their role, if any, in
either the anti-inflammatory actions of glucocorti-
coids or in disease is unknown. Therefore, these are
not discussed in this manuscript.
2.1 Glucocorticoid-Mediated Transrepression
GRa monomers are able to associate directly
with promoter-bound transcription factors such
as nuclear factor (NF)-kB and activator protein
(AP)-1.[19] This association allows GRa to be tar-
geted directly to the activated promoter region of
proinflammatory genes controlled by these tran-
scription factors. Thereafter, GRa facilitates silenc-
ing of gene transcription by modulation of critical
covalent modifications on the core histone proteins
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such as acetylation and methylation.[20-22] These
modifications are central in mediating conforma-
tional changes that regulate access for the tran-
scriptional machinery to the promoter region.[20]
GRa itself has no intrinsic enzymatic capacity to
directly modulate these histone modifications, but
recruits co-repressor complexes such as mamma-
lian Sin3a (mSin3a) and nucleosome remodelling
and deacetylase/Mi2 (NuRD/Mi2) complexes.[23,24]
These co-repressor complexes contain DNA and
chromatin-modifying enzymes, including methyl-
transferases and histone deacetylases (HDACs),
which ‘turn off’ gene transcription by altering the
covalent modifications on the core histone pro-
teins and DNA[21,25] (figure 1). The recruitment of
HDAC-2 appears to be of particular importance
for GRa-mediated transrepression. Specific reduc-
tion of HDAC-2 expression using small interfering
RNA (siRNA) abolishes glucocorticoid-GRa-
mediated repression of proinflammatory gene ex-
pression.[26] HDAC-2 induces gene silencing in a
nonspecific manner by removing the acetyl groups
from the amino terminal tails (deacetylation) of the
core histone proteins.[20] This enables DNA to re-
associate with the core histone proteins forming a
compact or ‘condensed’ tertiary chromatin struc-
ture which dislodges the transcriptional machinery
and prevents further binding.[20,27] HDAC-2 also
deacetylates GRa itself, which serves to enhance its
association to NF-kB.[26]
2.2 Glucocorticoid-Mediated Glucocorticoid
Receptor (GR)-a Transactivation
In addition to repression of gene expression,
GRa can also promote gene expression (transacti-
vation) by forming homodimers and directly bind-
ing to the glucocorticoid response element (GRE)
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Fig. 1. Diagrammatic representation of the basic mechanism by which glucocorticoid (GC) receptor-a (GRa) [a] represses transcription
factor-driven expression of proinflammatory genes (transrepression) and (b) activates gene expression from GC response element (GRE)
promoter sites. Nuclear factor-kB is represented by a heterodimer of its p50/p65 subunits. HAT = histone acetyltransferase; HDAC = histone
deacetylase; RNA Pol II =RNA polymerase II; TBP =TATA binding protein.
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promoter (figure 1). GRa-GRE binding induces
the expression of a number of anti-inflammatory
mediators including interleukin (IL)-10, secretory
leukocyte protease inhibitor and mitogen-activated
protein kinase (MAPK) phosphatase 1 (MKP-1).[28,29]
In addition, glucocorticoid repression of inflam-
matory genes under the control of NF-kB may
also be partly facilitated through GRa-mediated
induction of inhibitory protein kB a (IkBa) from
the GRE. The resulting elevated IkB expression
sequesters NF-kB to the cytosol where it is held in
an inactive cytoplasmic complex.[30]
Particular attention has been paid to the
glucocorticoid-dependent induction of MKP-1.
Induction of the potent proinflammatory p38
MAPK/NF-kB signalling pathway can regulate
GRa function (via p38 MAPK phosphorylation;
discussed in sections 2.4 and 4.3), which is in turn
regulated by GRa through induction of MKP-1
expression.[31,32] Adenoviral overexpression of
MKP-1 reduced p38 MAPK and NF-kB activa-
tion, and the expression of CXC chemokine
ligand 8 (CXCL8).[31] In addition, siRNA-medi-
ated knockdown of MKP-1 partially reverses
dexamethasone repression of TNFa-mediated
activation of p38MAPK. TNFa-inducedNF-kB-
mediated proinflammatory gene expression is
repressed by dexamethasone in the presence of
MAPK kinase 6 (MKK6), a p38 MAPK inhibi-
tor; however, blocking MKP-1 by addition of
MKP-1 siRNA diminishes this effect.[31] These
studies provide evidence for the direct impor-
tance of GRa transactivation in mediating the
anti-inflammatory actions of glucocorticoids.
However, GRa-mediated gene expression is
also thought to be responsible for many of the
unacceptable side effects seen with high doses of
glucocorticoids and is a common reason for the
withdrawal of high-dose oral glucocorticoids as
an anti-inflammatory therapy.
2.3 Relative Contribution of GRa
Transrepression and Transactivation in
Glucocorticoid Inflammatory Mediator
Suppression
GRa transactivation is widely associated with
the unacceptable side effects seen at higher doses
of glucocorticoids. Therefore, the relative con-
tributions of both transrepression and transacti-
vation may be therapeutically important if these
mechanisms can be selectively targeted. Trans-
genic mice expressing a mutant GRa, which is
unable to dimerise and thereby bind to the DNA
(GRadim mice) are able to repress inflammatory
responses induced by both local and systemic
lipopolysaccharide exposure comparable to wild-
type animals.[16] Therefore, it was proposed that
GRa DNA binding and consequent induction of
gene expression (transactivation) was non-essential
for the anti-inflammatory actions of GRa. How-
ever, further investigations using these mice in a
model of contact allergy demonstrated that the
anti-inflammatory response of glucocorticoids
was impaired in the GRadim mice.[33] This sug-
gests that the relative contributions of GRa
transrepression and transactivation may depend
on the inflammatory stimulus.
To date, more importance has been placed on
GRa transrepression in glucocorticoid-mediated
inflammatory repression. This is principally due
to greater experimental investigation into GRa-
mediated transrepression and concern over the
transactivational-related adverse effects rather
than substantial experimental evidence showing a
secondary/minor role for GR-mediated transac-
tivation in the glucocorticoid-mediated anti-
inflammatory action. Therefore, further, more
direct investigation is needed to decipher the real
contribution of GRa-meditated transactivation
in a range of inflammatory responses. Critically,
this must also be done using human cells and
tissues as murine cells do not express the GRb
isoform, which may play an important role (dis-
cussed in sections 2.5 and 4.4). Investigation in
primary human cells and tissues using well char-
acterized dissociated corticosteroids may resolve
this issue in the near future.
2.4 Regulation of GRa Function by
Phosphorylation
Phosphorylation plays an important role in
the regulation of GRa function.[34,35] Human
GRa is phosphorylated on at least five serine re-
sidues (S113, S141, S203, S211 and S226), which
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are positioned within the major transactivational
domain (AF1).[34] Although the exact functional
effects of phosphorylation at these sites are un-
clear, a number of studies have shown how they
may determine the activity of the AF1 domain on
GRa. Phosphorylation of S211 and S226 is
thought to be important for the transcriptional
activity of GRa, whilst S203 may be involved
in GRa translocation.[35,36] Phosphorylation of
S211 and S226 may also enhance the interaction
of GRa with co-regulators, including the vitamin
D3 receptor-interacting protein/thyroid receptor-
associated protein (DRIP/TRAP) complex and
the vitamin D receptor interacting protein 150
(MED14), as well as potentially influencing GRa
activity in a gene-selective manner.[35]
An array of kinases facilitates phosphoryl-
ation of GRa at distinct sites, thereby integrat-
ing GRa activation in cell-signalling pathways.
These include extracellular-regulated kinase
(ERK)-2, p38 MAPK, cyclin-dependent kinases
(CDKs) 1, 2 and 5, glycogen synthase kinase 3
(GSK3) and c-Jun N-terminal kinase (JNK).[36-38]
These kinases mediate phosphorylation that may
be either activational (CDK1, 2 and 5) or inhibi-
tory (JNK, GSK3). In addition, certain kinases
such as p38 MAPK appear to facilitate both
activation and inhibition of GRa activity in a
cell-specific manner.[36,39]
2.5 A Role for GRb?
The human glucocorticoid gene encodes two
isoforms of the GR receptor generated by splice
variants resulting in expression of the GRa and
GRb isoforms.[40] In contrast to the canonical
GRa, GRb is an orphan receptor which is loca-
lized to the nuclear compartment and is devoid of
the ability to bind glucocorticoids.[41] The sole
function of GRbwas thought to be as a dominant
negative regulator of GRa through competition
for co-regulators including the GR interacting
protein 1 (GRIP-1).[40,42] However, although the
GRb isoform lacks the ability to bind to gluco-
corticoids, recent evidence suggests that, in ad-
dition to its dominant negative regulatory role for
GRa function, GRb may also facilitate direct
transcriptional effects of its own. Although no
endogenous ligands for GRb have been identi-
fied, Cidlowski and colleagues[41] demonstrated
that GRb is also localized in the cytosol using
COS-1 and U-2 OS cells and has the ability to
bind the synthetic GRa receptor antagonist
mifepristone (RU486), which mediated nuclear
translocation of GRb. Interestingly, in the ab-
sence of GRa, microarray analysis showed that
GRb was capable of regulating gene transcrip-
tion, which was diminished upon binding of mi-
fepristone.[41] Additional studies using Hela cells
have also shown that GRb has intrinsic gene-
specific transcriptional activity (both negative
and positive), where the majority of affected
genes were distinct from those regulated by
GRa.[43] These recent findings clearly demon-
strate that the role of GRbmay be more complex
and important than its perceived single role as a
dominant negative regulator of GRa. The further
complication of additional splice variants with
potentially distinct functions also needs further
examination.[44] However, these are novel dis-
coveries and further investigations, particularly
in primary human cells, are needed to elucidate
the extent and role of these proposed additional
GRb actions as well as any cellular or tissue
specificity.
3. Relative Glucocorticoid Insensitivity
in Respiratory Disease
3.1 Severe Asthma
Allergic responses in the airways of patients
with asthma may induce narrowing of the large
airways that is largely reversible by broncho-
dilator drugs such as short- and long-acting b2
agonists. The allergic response in asthma is
characterized by an adaptive/T helper (Th) type 2
cell-mediated response that induces an isotype
switch in B cells for the production of im-
munoglobulin (Ig) E. This in turn initiates mast
cell degranulation through activation of high-
affinity IgE receptors expressed on the mast cells,
and also through the induction of eosinophilic
activation and responses.[10] Low doses of inhaled
glucocorticoids effectively control the inflam-
matory response in most patients with asthma
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and are considered a first-line treatment.[45] How-
ever, a small proportion of asthmatic patients
have a severe formof asthma that is not adequately
controlled by existing asthma medications, in-
cluding glucocorticoids, even when used at high
doses.
The inflammatory response in the lungs of
patients with severe (relatively glucocorticoid-
‘insensitive’ or -‘unresponsive’) asthma is not
different to that observed in the lungs of patients
with mild/moderate (relatively glucocorticoid-
‘sensitive’ or -‘responsive’) asthma, as demon-
strated by an elevation in both eosinophil and
leukocyte numbers in bronchial biopsies from
patients with severe asthma.[46] It is clear that pa-
tients with severe asthma are treated with much
higher doses of glucocorticoids, which therefore
gives rise to the idea of relative glucocorticoid
insensitivity.[47] This relative glucocorticoid
insensitivity is supported by observations that
glucocorticoids fail to repress the release of pro-
inflammatory mediators from both circulating
inflammatory cells (peripheral blood mono-
nuclear cells [PBMCs]) and lung macrophages
(obtained from bronchoalveolar lavage) induced
by lipopolysaccharide from patients with severe
asthma as compared with patients with mild/
moderate asthma, including CXCL8, TNFa and
granulocyte macrophage-colony stimulating factor
(GM-CSF).[48,49] The ratio of matrix metallo-
protease (MMP)-9 to the tissue inhibitor of
MMP (TIMP)-1 is higher in the lungs of patients
with severe asthma.[50] Glucocorticoids elevate
TIMP1 expression but this response is absent in
alveolar macrophages from patients with severe
asthma, which may contribute to the abnormal
tissue remodelling in the airways of severe asthma
leading to a reduction in lung function and b-
agonist reversibility in these patients.[2,50] Indeed,
Macedo et al.[46] have recently shown that there is
a greater degree of subepithelial fibrosis and air-
way smooth muscle in patients with severe asth-
ma as compared with non-severe asthma.
Interestingly, the inflammatory component of
severe asthma may have some similarities to the
inflammatory response seen in COPD.[10] This is
particularly apparent with the presence of an in-
nate/Th1 response in addition to the Th2 cells that
predominate in mild/moderate asthma as well as
more CD8+ T cells.[10,51-53] In contrast to mild/
moderate asthma, patients with severe asthma
also have increased neutrophils in their sputum,
increased CXCL8 and TNFa, and an elevated
oxidant burden in the lung.[51,54-57]
Asthmatic patients who smoke (accounting
for ~25% of asthmatic patients) also have a re-
duced response to inhaled and oral glucocorti-
coids, and develop more severe asthma with an
associated decline in lung function compared
with asthmatic patients who do not smoke.[58,59]
These smoking asthmatic patients also have an
increase in sputum neutrophils and CXCL8, which
is more closely associated with severe asthma and
COPD than with mild/moderate asthmatic
patients who do not smoke.[59] The evidence for
this smoking-related effect is further found in
COPD (discussed in section 3.2) where the major
aetiological factor is cigarette smoke, which may
also contribute to the development of the relative
glucocorticoid-insensitivity seen this disease.[2,60]
3.2 Chronic Obstructive Pulmonary
Disease (COPD)
COPD is characterized by airflow limitation
that is progressive, poorly reversible and is asso-
ciated with airway remodelling and an enhanced
chronic inflammation in the lungs.[61] Although
cigarette smoke is the main aetiological factor in
the development of COPD, the exact mechanism
and contributing factors involved in the devel-
opment of COPD are complex and not well un-
derstood. Airflow limitation is a central feature
of both COPD and asthma; however, an im-
portant defining factor differentiating these two
diseases is that the airflow limitation in asthma is
largely reversible, whereas it is largely irreversible
in COPD.[62] A seminal study from Hogg and
colleagues[62] identified a potential cause of the
airflow obstruction in COPD to be remodelling
of the small airways, which correlated with dis-
ease progression.
Another defining factor between COPD and
asthma is the type of underlying inflammation in
the lungs. The inflammation in the lungs of
COPD patients is predominantly driven by an
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innate/Th1 type immune response, whereas in
asthma it is a predominantly adaptive/Th2 immune-
mediated response.[10,60] The chronic enhanced
lung inflammation in COPD is associated with
an elevation in the number of macrophages,
neutrophils, Th1 and type 1 cytotoxic T (Tc1)
cells and CD8+ T cells in the lung.[10,51,60] In ad-
dition, COPD patients have mucus hypersecre-
tion and reduced mucociliary clearance, which is
a major contributing factor in bacterial coloni-
zation and infection resulting in exacerbations as
well as varying degrees of emphysema (alveolar
wall destruction) and chronic bronchitis.[60,63,64]
Unlike asthma patients, the majority of pa-
tients with COPD respond very poorly to inhaled
and oral glucocorticoids, even at high doses.
Glucocorticoid treatment in patients with COPD
has no impact on the rate of decline in lung
function, disease progression or mortality. There
is evidence that glucocorticoids may have a modest
beneficial effect on the number of exacerbations,
although this has recently been questioned.[65,66]
The inflammatory response seen in the lungs
of COPD patients is glucocorticoid insensitive.
A number of studies have shown that inhaled
glucocorticoids have no impact on the numbers
of inflammatory cells in the lungs or on the re-
lease of proinflammatory mediators in COPD
patients.[29,67,68] In addition, glucocorticoids fail
to repress the release of proinflammatory med-
iators from alveolar macrophages obtained from
the bronchoalveolar lavage fromCOPDpatients.[69]
3.3 Cystic Fibrosis
CF is one of the most common lethal genetic
diseases in Caucasians, and is characterized by an
aggressive and predominantly innate/Th1 in-
flammatory response with extensive destruction
of the lungs.[70] In contrast to both COPD and
severe asthma, the underlying cause of CF is
known. The development of CF is a result of a
mutation in the gene that encodes the CF trans-
membrane conductance regulator (CFTR).[70]
The CFTR is expressed in epithelial cells and
leukocytes, and acts mainly as a chloride channel,
although it has a plethora of other key regulatory
functions, including regulation of adenosine tri-
phosphate channels, intracellular vesicle trans-
port, acidification of intracellular organelles, and
inhibition of both epithelial sodium channels and
endogenous calcium-activated chloride chan-
nels.[70] The development of CF is often rapid; the
lungs of children with CF appear normal at birth,
but then rapidly become infected and inflamed.
The influx of inflammatory polymorphonuclear
cells is associated with an imbalance in pro- and
anti-inflammatory mediators including an eleva-
tion in NF-kB signalling, and increased IL-6,
CXCL8, TNFa and ecosanoid expression, whilst
the levels of anti-inflammatory mediators such as
IL-10, lipoxin and docosahexaenoic acid are re-
duced.[70-73] Despite the importance of the in-
flammatory response in the pathogenesis of CF,
the current therapies are ineffective. Similarly to
COPD and severe asthma, glucocorticoids are
ineffective at controlling the aggressive inflam-
matory response seen in CF. Ibuprofen is com-
monly used as an alternative anti-inflammatory
therapy as it is inexpensive, has relatively few
adverse effects, and has been shown to be bene-
ficial when given before the onset of severe inflam-
mation and pathological changes in the lung.[74]
However, due to the aggressive nature of the in-
flammatory response in CF and its undoubted
importance in the progression of the disease, the
lack of an effective broad-ranging and powerful
anti-inflammatory drug such as a functional
glucocorticoid-type drug represents a major un-
met medical need.
4. Underlying Mechanisms of
Glucocorticoid Insensitivity
The molecular mechanisms of the relative
glucocorticoid insensitivity in these respiratory
diseases remain both unclear and understudied.
Although there is a recognised inherent variation
in glucocorticoid responsiveness between differ-
ent cell types and tissues, the majority of cells that
make up the lung and the infiltrating inflamma-
tory cells are responsive to glucocorticoids.[75]
One exception to this are neutrophils, which are
less responsive to glucocorticoids (discussed in
detail in section 4.5). Furthermore, many other
inflammatory conditions involving many of these
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cell types are well controlled. It is therefore un-
likely that an intrinsic relative glucocorticoid
unresponsiveness of a particular cell type or of
the lung itself can fully account for the reduction
of glucocorticoid-insensitivity seen in CF, severe
asthma and COPD.
There may also be some commonality in the
mechanisms of glucocorticoid insensitivity be-
tween these diseases and indeed in other diseases
that respond relatively poorly to glucocorticoids.
Common immunological features of severe asth-
ma, COPD and CF include an enhanced in-
flammatory response that either has components
of or is predominantly driven by the innate/Th1
type immune response. The innate/Th1 response
itself is well documented as responding well to
glucocorticoids; however, an ‘enhanced’ inflam-
matory response may incorporate an overriding
factor. One of the more prominent theories im-
plicated is elevated or ‘overriding’ oxidant bur-
den in the lungs[60,76] (figure 2). This concept is
attractive not only from the experimental and
mechanistic evidence, but also by its alignment
with other proposed mechanisms. However, se-
vere asthma, COPD and CF are often studied
separately, whereas an approach to dissect the
pathways governing glucocorticoid function across
these diseases may prove more fruitful. Other
proposed mechanisms, both distinct and aligned
with oxidative stress, include genetic factors,
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altered kinase signalling, elevated GRb expres-
sion and alteration of the histone acetylation/
deacetylation balance (figure 3).
4.1 Oxidative Stress and Histone Deacetylase
Activity
An elevated oxidant burden in the lungs is a
major component of severe asthma, COPD and
CF, which may be a central factor in the devel-
opment of relative glucocorticoid insensitivity in
these diseases.[60,76] This oxidant stress may be
derived from both exogenous sources such as
pollution and cigarette smoke and endogenously
from the respiratory burst of proinflammatory
cells such as macrophages and neutrophils.
Under physiological conditions, oxidants and
the redox state of the cell are an integral part of
cellular signalling and function, including that
of GR.[77,78] However, a significant elevation in
oxidants can overcome both intra- and extra-
cellular antioxidant defences, and can alter sig-
nalling pathways and protein function.[79] The
role of additional exogenous oxidative stress such
as cigarette smoke is highlighted by both its in-
duction of reduced glucocorticoid insensitivity in
experimental models, the development of gluco-
corticoid insensitivity in COPD and the devel-
opment of relative glucocorticoid insensitivity
in patients with mild/moderate asthma who
smoke.[58,60,80,81] Oxidative stress also plays a key
role in the inflammatory processes associated
with CF.[82]
A central factor in both an oxidant-mediated
enhancement of inflammatory responses and de-
velopment of relative glucocorticoid insensitivity
may be facilitated by a direct alteration of the
acetylation-deacetylation balance of the core
histones.[83] Oxidative stress leads to a reduction
of HDAC-2 activity (acute exposure) with an
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Fig. 3. Diagrammatic representation of the proposed mechanisms by which glucocorticoid receptor-a (GRa) function may become defective
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additional reduction in HDAC-2 expression
(seen with more chronic exposures) in in vitro and
in vivo models.[80,84,85] The reduction in both
activity and expression results from covalent
modifications, including hyperphosphorylation,
nitration and carbonylation mediated by reactive
oxygen species (e.g. reactive carbonyls, reactive
nitrogen species), and by kinase signalling path-
ways activated by the oxidative stress.[83,86] These
modifications directly result in the reduction
HDAC-2 activity and also reduce its expression
by marking it out for proteasomal degrada-
tion.[84,85,87-89] As histone acetylation is a key fac-
tor in gene transcription, this oxidant-mediated
loss of HDAC activity and/or elevated histone
acetyltransferase (HAT) activity is likely to con-
tribute to the enhanced inflammatory responses
in these diseases (figure 2).
HDAC-2 activity and expression is reduced in
both COPD and severe asthma, with the reduc-
tion of activity in the peripheral lungs of COPD
patients correlating with disease severity.[49,90,91]
Importantly, HDAC-2 is fundamental for func-
tional GRa transrepression of proinflammatory
genes, and a reduction in its activity/expression
mediated either by oxidative stress or by siRNA
severely impairs GRa transrepression of proin-
flammatory mediators.[26] Conversely, protection
or restoration of HDAC-2 activity in in vitro and
in vivomodels restores glucocorticoid responsive-
ness.[81,92] Therefore, the reduction in HDAC-2
activity and expression seen in COPD and
severe asthma is likely to be an important factor in
the mechanisms of the relative glucocorticoid
insensitivity seen in these diseases (figure 2).
Total HDAC activity measurement in CF has
only been performed as part of one study and
there was no alteration compared with healthy
lungs.[91] However, this study was performed on
total lung extracts and alterations may be more
local or cell-type restricted, which may be missed
in a relatively crude total lung analysis. Indeed,
recent studies have shown that the loss of CFTR
may result in a reduction of HDAC-2 activity in
airway epithelial cells.[93] In addition, oxidative
stress-induced hyperacetylation of the CXCL8
promoter in CF airway cell models and HAT
activity may be elevated in the peripheral lungs
of CF patients.[91,94] However, with so few studies
in CF relating to the HDAC/HAT balance, the
evidence of a role for HDAC-2 activity in the re-
lative glucocorticoid insensitivity in CF appears
promising but is not yet conclusive. This highlights
a critical need for further investigations relating to
glucocorticoid insensitivity in this disease.
4.2 Genetics
A number of studies have linked genetic mu-
tations and alterations in cellular expression with
the development of glucocorticoid insensitivity,
as elegantly reviewed by Gross et al.[95] Early
studies identified a higher incidence of relative
glucocorticoid-insensitive asthma within families,
which indicated that there may be a genetic link
to the development of glucocorticoid insensiti-
vity.[96] Genetic analysis of PBMCs have identi-
fied 11 genes that discriminate between relative
glucocorticoid-insensitive and glucocorticoid-
sensitive asthmatic patients, including those for
several asthma-related proinflammatory signal-
ling pathways, suggesting that there may be a
genetic factor in the development of relative
glucocorticoid-insensitive asthma.[97] A link be-
tween genetic factors and the development of rela-
tive glucocorticoid insensitivity in COPD has not
been directly assessed; however, there is evidence
that genetic susceptibility is likely to play a role.
Studies investigating the antioxidant capacity in
the lungs of COPD patients and smokers suggest
that subjects who develop COPD have a reduced
capacity to elevate their antioxidant defences,
which may, in part, account for the development
of COPD in a subset of smokers (~20%).[98-100]
Furthermore, given the likely central role for oxi-
dant stress in the development of glucocorticoid
insensitivity, the reduced antioxidant capacity is
also likely to contribute to the development of a
relative glucocorticoid insensitivity in COPD.
The genetics of severe asthma versus mild/
moderate asthma are currently being intensively
investigated, but as of yet there has been no
indication of genetic link with antioxidant capa-
city that may thereafter play a role in gluco-
corticoid insensitivity. In CF, the onset and level
of the inflammatory response and ensuing lung
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destruction is aggressive and a clear driving factor is
represented by the mutation of the CFTR gene.
Therefore, unlike the slow progression and devel-
opment of COPD where, in addition to other fac-
tors, the oxidant imbalancemay takemany years to
be overcome, an underlying genetic susceptibility in
CF relating the antioxidant capacity is unlikely to
play a central role in either the development of the
disease or glucocorticoid insensitivity.
4.3 Kinase Signalling
The activation of signalling kinases is a fun-
damental part of physiologically controlled in-
flammation. However, many of these kinases
such as p38 MAPK, GSK-3b, ERK1/2 and JNK
also regulate GRa activity andmay also influence
its gene specificity.[101,102] The activity of ERK1/2,
JNK and p38MAPK are elevated in severe asthma
compared with mild/moderate asthma and the
elevation of p38 MAPK has also been linked to
elevated phosphorylation of GRa leading to re-
duced ligand-binding affinity.[103,104] COPD pa-
tients also display altered kinase signalling with
an elevation in the activity of both p38 MAPK
and JNK compared with healthy smokers.[105,106]
Elevated p38 MAPK may also be directly re-
sponsible for reduced GRa function in severe
asthma through a reduction in the expression of
MKP-1.[49] Altered kinase signalling may also
diminish GRa function indirectly through im-
pairment of HDAC-2 activity by elevated PI3Kd
signalling in COPD.[81,107]
In CF, the absence of the CFTR induces an
intrinsic activation of proinflammatory tran-
scription factors including AP-1 and NF-kB by
mechanisms involving ERK1/2 and IKK signal-
ling pathways.[108] This activation is then conse-
quently sustained via autocrine stimulation by
proinflammatory mediators such as IL-1b.[108]
Both ERK1/2 and p38 MAPK may also be in-
volved in the enhanced proinflammatory response
in CFTR defective cells.[109] Further studies are
needed to directly investigate the activation of
these kinases in CF in relation to altered GRa
function and glucocorticoid insensitivity, and the
negative feedback regulatory mechanisms utilised
by GRa such as MKP-1 expression.
4.4 GRb Expression
Classically, GRb is perceived as a negative
regulator of GRa and its level of expression
would thereby dictate the relative functional ef-
fectiveness of GRa. Consequently, the expression
of GRb correlates with effective glucocorticoid
function, particularly in cells/tissues.[75,110] It is
therefore likely that a high GRb to GRa ratio in
disease would impair GRa function contributing
to glucocorticoid insensitivity. However, the level
of GRb in disease is a controversial area. Gluco-
corticoid insensitivity in severe asthma was in-
itially found to be independent of GRa and GRb
expression.[111] Other studies have shown a re-
lationship between GRb expression and severe
asthma.[112] In COPD, the expression of GRa is
reduced with no elevation of GRb levels.[81,113]
No studies have looked at the expression of GRa
or GRb in CF. Therefore, with so few studies
assessing the relative expressions of GRa and
GRb in these diseases it is difficult to assign a role
for GRb in the development of glucocorticoid
insensitivity with any confidence. More studies
are therefore needed to clarify their relative ex-
pression in disease.
A role for GRb may also be found in light of
recent evidence that it has an intrinsic transcrip-
tional activity and may also be able to bind li-
gands.[41,43] In light of these novel and important
observations, the role of GRb in primary human
cells and tissues, including those from disease,
must be established. Thereafter, any potential
impact on glucocorticoid insensitivity may be
assessed with more confidence than a simplistic
dominant negative regulation of GRa.
4.5 Neutrophils andNeutrophilic Inflammation
The majority of cells involved in the patho-
genesis of lung diseases are responsive to gluco-
corticoids. However, neutrophils and neutrophilic
inflammation are relatively unresponsive to
glucocorticoid-mediated immunosuppression com-
pared with other cell types.[81,114,115] Studies have
shown a relatively higher expression of GRb and a
further induction of GRb expression upon stimu-
lation, which could thereafter impair the functional
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effectiveness of GRa and contribute to a relative
reduction in glucocorticoid sensitivity.[110] However,
other studies have shown low expression of GRb
and therefore the precise relative expression levels of
both GRa and GRb in neutrophils remains both
unresolved and controversial.[116]
Importantly, neutrophil-associated exacerba-
tions of severe asthma and COPD are also poorly
controlled by glucocorticoids.[114,115] However, it
has not been determined whether this is an exten-
sion of the existing glucocorticoid insensitivity or
if there is an additional unresponsiveness mediated
by the acute elevation in neutrophils during the
exacerbation. It is therefore feasible that the pre-
sence of neutrophils in both the stable and acute
inflammatory responses in severe asthma, COPD
and CF may contribute, in part, to their overall
reduced responsiveness to glucocorticoid treatment.
Despite an apparent lack of glucocorticoid-
mediated immunosuppression in neutrophils and
neutrophilic inflammation, glucocorticoid treat-
ment of neutrophils elicits GRa-dependent re-
sponses, most notably a delay in their constitutive
apoptosis.[117,118] These studies demonstrate that
glucocorticoids are able tomediate importantGRa-
specific responses in neutrophils. Induction of these
responses may have important clinical implications,
particularly in severe asthma and COPD, which
despite being relatively glucocorticoid insensitive, is
still treated with high levels of glucocorticoids.
Further investigations are needed to depict the re-
levance and possible roles of these GRa-dependent
responses when treating a neutrophil-associated in-
flammatory response with glucocorticoids.
4.6 Impairment of GRa Transrepression or
Transactivation, or Both?
Most functional studies concerning glucocorti-
coid insensitivity in models mimicking aspects of
airway diseases such as asthma and COPD look
at the ability of glucocorticoids to repress the pro-
inflammatory genes, co-factors concerned with
GRa transrepression or the inflammatory cell in-
flux.[26,49,80,81,90,92] A failure of glucocorticoids to
repress these inflammatory factors is seen as gluco-
corticoid insensitivity. However, alterations in
GRa transactivation in patients with relative gluco-
corticoid insensitivity has not been extensively
assessed andmay also be important, particularly as
the potential contribution of GRa transactivation
to the full anti-inflammatory actions of gluco-
corticoid in responsive airway diseases has not
been established. Of course, the major reason that
patients have limited or are withdrawn from glu-
cocorticoid treatment is unacceptable side effects,
which in turn are classically attributed to GR
transactivation. Therefore, this would suggest that
GRa transactivation is functional in these relative
glucocorticoid-insensitive patients. However, re-
cent evidence suggests that the regulation of spe-
cific genes by GRa may be dependent on GRa
phosphorylation at specific sites.[40,101,102] It could
therefore be speculated that the phosphoryla-
tion status of GRa is altered in relative gluco-
corticoid-insensitive patients in such a manner that
transcription of genes associated with its anti-
inflammatory action are impaired but not those
largely associated with mediating glucocorticoid-
mediated adverse effects. Furthermore, studies
using the GRadrim mice, which are essentially de-
void of GRa transactivation, show that these mice
still have adverse effects from glucocorticoid
treatment.[119] Therefore, we cannot rule out both
a substantial contribution of GRa transactivation
to glucocorticoid-mediated immunosuppression in
glucocorticoid-responsive airway diseases and there-
after any impairment of GRa transactivational
immunosuppression in glucocorticoid-insensitive
airway diseases. It is therefore essential that further
studies attempt to depict the role of GRa trans-
activation in airway diseases as this may then
influence future therapeutic strategies. Investigation
using recently described dissociative glucocorti-
coids in patients with severe asthma and COPD
may resolve many of these issues.[120]
5. Therapeutic Approaches to Overcome
Glucocorticoid Insensitivity in COPD and
Asthma: Alternative Treatments and
Restorative Approaches
5.1 Alternative Anti-Inflammatory Therapeutic
Targets
Selective inhibition of single inflammatory
mediators that are thought to be important in
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COPD and asthma have not proven success-
ful.[11] This is likely to be due to the complex
nature of the inflammatory responses in these
diseases where removal of proinflammatory sig-
nalling derived from a single proinflammatory
mediator may simply be compensated by the
multitude of downstream intracellular signalling
networks activated by the overall inflammatory
response. Therefore, an effective alternative anti-
inflammatory strategy must be directed against a
target that has broad-ranging anti-inflammatory
effects such as those seen with glucocorticoids.
One attractive strategy that is being investigated
is the inhibition of selective protein kinases,
which act as signalling messengers for multiple
inflammatory stimuli. These kinases are a pivotal
part of multiple interconnecting inflammatory
pathways and, therefore, regulate the expres-
sion of a plethora of different proinflammatory
mediators.[121,122] An obvious hurdle with tar-
geting these kinases is that many are ubiqui-
tously expressed and in addition to inflammatory
signalling are also involved in critical physio-
logical cellular processes. However, specific in-
hibition of selected isoforms and the relatively
unique opportunity to deliver therapies locally
to the lung may provide an avenue to over-
come possible toxic effects. Two such proteins
kinase targets, phosphoinositol 3-kinase (PI3K)
and p38 MAPK kinase, are discussed in the fol-
lowing sections.
5.1.1 p38 Mitogen-Activated Protein Kinase
There are four p38 MAPK isoforms, a, b,
g and d, which are encoded by separate genes and
are expressed in a tissue-dependent manner. p38
MAPK is a centralmediator inmany of the inflam-
matory signalling pathways, including activation
of NF-kB, regulation of GRa and marking out
proinflammatory genes for early gene transcrip-
tion through phosphorylation of histone 3 at
serine 10.[123] The specific roles of the individual
p38MAPK isoforms in the inflammatory response
are unknown due to a lack of selective pharmaco-
logical tools; however, selective inhibition of
the p38 MAPK a isoform potently inhibits the
release of many proinflammatory cytokines includ-
ing TNFa, IL-6, CXCL-8 and GM-CSF.[124,125]
Many of these pathways and genes are prominent
in the relatively glucocorticoid-insensitive inflam-
matory responses seen in severe asthma, COPD
and CF.[51] Selective inhibition of p38 MAPK
also reduced the inflammatory response in nasal
biopsies from CF patients, including CXCL8 re-
lease, COX-2 upregulation and neutrophil migra-
tion, although the contribution of the individual
p38 MAPK isoforms has yet to be assessed.[126]
Therefore, selective inhibition of p38MAPKmay
also prove to be an effective anti-inflammatory
therapeutic strategy in CF.
As oxidative stress and oxidant-driven inflam-
mation is such a prominent component of these
diseases, which can not only alter drug targeting
but may also induce glucocorticoid insensitivity,
it is critical to assess if these inhibitors are able to
suppress oxidant-driven inflammatory responses
where glucocorticoids fail.[69,127] Encouragingly,
inhibition of p38MAPK a also reduces the inflam-
matory response in cigarette smoke-mediated
glucocorticoid-insensitive models in vivo.[128] In
addition, inhibition of p38 MAPK may also im-
prove glucocorticoid function in PBMCs from
COPD patients.[129]
Consequently, direct inhibition of p38 MAPK
has been proposed as a potential novel anti-
inflammatory strategy and a number of selective
p38 MAPK a inhibitors are currently under de-
velopment for respiratory disease.[122]
5.1.2 PI3Kd/c
The lipid kinases PI3Kd and PI3Kg have a
relatively restricted expression to mast cells and
leukocytes, and are central in mediating both the
innate and adaptive inflammatory responses.[130]
Selective inhibition of these PI3K isoforms has
proven particularly successful in models of allergic
inflammation by reducing airway hyperrespon-
iveness, eosinophilia and mast cell degranulation,
as well as B- and T-cell function.[130-135] Conse-
quently, a number of small-molecule inhibitors of
these isoforms are currently under development
for asthma.[136]
In contrast to allergy, the roles of these iso-
forms in diseases that are driven by innate (Th1)
immunity such as COPD and CF, or that have a
Th1 component such as severe asthma, have not
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been directly studied. However, the impact of
these isoforms on the key cells, including neu-
trophils and macrophages, involved in these
diseases has been investigated. Neutrophil mi-
gration, directional chemotaxis and respiratory
burst are dependent on PI3Kg and d signal-
ling.[134,137,138] Monocyte recruitment into the
lungs is also dependant on PI3Kd signalling.[139]
In addition, Th1 and Tc1 cells are now proposed
to be important in the orchestration of chronic
inflammatory responses. PI3K signalling also
appears to be important in T-cell trafficking and
the retention of specific T cell types, such as Tc1
cells.[140]
Therefore, the role of PI3Kg and d in the reg-
ulation of the innate immune response and the
ability to selectively target these isoforms pre-
sents an attractive and novel anti-inflammatory
therapeutic strategy for the treatment of severe
asthma, COPD and CF.
5.2 Therapeutic Targets for the Restoration
of Glucocorticoid Function
In addition to novel anti-inflammatory targets,
another strategy being pursued is the pharmaco-
logical restoration of glucocorticoid function,
which would have the benefit of re-establishing
an effective anti-inflammatory therapy that was
well profiled in terms of application, drug inter-
actions and adverse effects. Restoration of gluco-
corticoid function has been achieved both in
in vitro and in vivo glucocorticoid-insensitive mod-
els and in primary cells from patients with disease
through selective inhibition of the PI3Kd/Akt
pathway.[81,107] These targets along with addi-
tional strategies are discussed in the following
sections.
5.2.1 Antioxidants
As oxidant stress is proposed to play a central
role in not only the development and progression
of COPD, severe asthma and CF but also in the
mechanisms of relative glucocorticoid insensi-
tivity, it would be obvious to directly target this
oxidant stress with antioxidants. A number of
studies have suggested that use of antioxidant
supplements such as N-acetyl-cysteine (NAC) or
an increase in dietary antioxidants may be bene-
ficial in COPD.[141,142] This is an attractive ther-
apeutic strategy; however, one of the major
hurdles is that antioxidants have a poor bio-
availability and attempts to deliver an effective
concentration to the lungs has proven difficult,
with little clinical benefit seen in COPD to
date.[143,144] If bioavailability and delivery hur-
dles are overcome and antioxidant drugs such as
NAC are able to be delivered into the lung at an
effective concentration, then it is likely that they
would have a beneficial impact on the function of
inhaled glucocorticoids.
5.2.2 Long-Acting b2 Agonists
Long-acting b2 agonists (LABAs) are broncho-
dilator drugs used in both asthma and COPD.
Although their use as a monotherapy is contro-
versial, their use as a combination therapy with
inhaled glucocorticoids has been shown to have
several beneficial effects, including improved gluco-
corticoid function.[45,145] When inhaled gluco-
corticoid therapy alone fails to control asthma,
addition of a LABA as a combination therapy
improves symptom score, improves lung function,
reduces the use of rapid-acting b2 agonists
and reduces the number of exacerbations.[45]
Several large-scale studies have demonstrated
that use of LABAs in combination with inhaled
glucocorticoids in patients with moderate-to-
severe COPD improved lung function (although
it does not influence its long-term deteriora-
tion), exacerbations, breathlessness and health
status.[145]
The exact molecular mechanisms of this im-
proved glucocorticoid function remain unclear,
but it is thought that LABAs may improve the
penetration of inhaled glucocorticoids into lung
cells. Although the evidence is clear that a com-
bination therapy of LABA-inhaled glucocorti-
coid improves symptoms and lung function in
both asthma and COPD compared with inhaled
glucocorticoids alone,[146] there is little evidence
to suggest that their use results in a substantial
improvement in glucocorticoid immunosuppres-
sion and ultimate disease progression. Therefore,
the additional use of an effective anti-inflammatory
is still required in these diseases.
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5.2.3 Theophylline
Several studies have shown that the first-
generation bronchodilator theophylline used at low
concentrations restored glucocorticoid function
in an HDAC-2-dependent manner.[92,127,147,148]
Enhancement of glucocorticoid function by
theophylline has been seen clinically for a number
of years where it has been used in patients with
moderate to severe asthma.[147,149] However, al-
though theophylline may act through a number
of pathways including that of PI3Kd/Akt (dis-
cussed in section 5.2.4), the exact target(s) by
which theophylline acts at these low concentra-
tions has not yet been established. Interestingly,
the binding profile of theophylline is altered un-
der conditions of oxidative stress, which may ex-
plain why it has no apparent impact on HDAC-2
activity in non-oxidant stressed cells.[127] Im-
portantly, this finding may also have wider im-
plications in terms of drug binding and targeting
in diseases with a prominent component of oxi-
dative stress and should be taken into considera-
tion in the development of therapies for these
diseases.
5.2.4 PI3Kd
In models of oxidant-mediated glucocorticoid
insensitivity, inhibition of the PI3K/Akt path-
way also restores glucocorticoid function in an
HDAC-2-dependent manner.[81] Our studies
using selective small molecule inhibitors and
transgenic mice in oxidant-mediated glucocorti-
coid insensitivity have revealed that it is the
PI3Kd isoform that is responsible for this ac-
tion.[81] Furthermore, selective inhibition of
PI3Kd restores glucocorticoid function in pri-
mary cells fromCOPD patients as compared with
age-matched smoking controls.[107] The precise
mechanisms by which inhibition of PI3Kd sig-
nalling restores glucocorticoid function is not
clear but appears to involve the protection of
HDAC-2 activity by reducing oxidant-mediated
hyperphosphorylation and nitration.[81] In addi-
tion, abolition of PI3Kd and g signalling also
protects the expression of other key components
of the HDAC-2-containing co-repressor com-
plexes (including Mi2 expression), which are re-
cruited by GRa to mediate gene repression.
However, PI3Kd signalling is an early event oc-
curring at the inner phospholipid layer of the cell
surface membrane and is therefore not likely
to directly interact with HDAC-2 or other co-
repressors. PI3Kd signalling is activated by
oxidative stress and is the major PI3K isoform
responsible for activation of Akt.[107,150] Akt may
thereafter act directly or on signalling kinases
further downstream, although extensive investi-
gations are still needed to elucidate the signalling
pathways that link oxidant activation of PI3Kd/
Akt and their protective effects on HDAC-2/
co-repressor expression and activity.
Therefore, as small-molecule inhibitors of
PI3Kd and dual inhibitors of PI3Kd/g are cur-
rently being considered for allergic disease, these
findings represent a significant development in a
possible therapeutic strategy for the restoration
of glucocorticoid function in COPD, which may
also be applicable to severe asthma and CF.
6. Conclusions
Relative glucocorticoid-insensitive inflamma-
tion is an unmet medical need in a number of
diseases, including severe asthma, COPD and
CF. The clinical significance of this relative gluco-
corticoid insensitivity in these diseases, which
include disease management problems and cost
burden, has led to increasing investigation into
new effective anti-inflammatory strategies in
what has been an understudied area.
Development of inhibitors against novel tar-
gets with broad-ranging anti-inflammatory func-
tions such as p38 MAPK a and PI3Kd/g, which
may also act to restore the function of glucocor-
ticoids, may provide an effective therapeutic
strategy against the enhanced glucocorticoid-
insensitive inflammation seen in these diseases.
However, despite the identification of the impor-
tance of oxidant-mediated alterations in kinase
signalling and co-repressor expression/activity,
the precise mechanism(s) of the relative gluco-
corticoid insensitivity in these diseases still re-
main unknown. Due to the complexity of the
inflammatory responses in these diseases, which
include components of both the innate and
adaptive immune systems, oxidant stress and
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protease imbalance, it is likely that the mechan-
ism(s) by which glucocorticoid function is impaired
will be complex and multifaceted. However,
given the similarities in aspects of the inflamma-
tion present in the lungs of patients with severe
asthma, COPD and CF, there may be common
mechanisms (such as those mediated by oxidant
stress) that may provide a viable therapeutic
strategy applicable across these diseases. It is
therefore important that all of the potential
mechanisms of relative glucocorticoid insensiti-
vity in these diseases are elucidated to provide
a clearer picture from which effective alterna-
tive anti-inflammatory and/or glucocorticoid-
restorative therapies may be developed.
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